Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › First Light Bio Developing Single-Molecule Counting Tech to Detect C. Diff. Toxins

First Light Bio Developing Single-Molecule Counting Tech to Detect C. Diff. Toxins

Jun 19, 2018
|
Leo O'Connor
Premium

NEW YORK (360Dx) – First Light Biosciences is developing a molecule counting technology that detects Clostridium difficile toxin in stool samples with an eye on providing a more accurate testing option for clinicians struggling with the global growth of infections.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

  2. DiaSorin to Acquire Luminex for $1.8B

  3. Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

  4. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  5. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.